5 unchanged sentences
(incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 27, 2023).
−Removed: 10.1* Form of Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks Holdings, Inc.
−Removed: 2021 Incentive Award Plan
−Removed: 10.2* Form of Performance-Based Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks Holdings, Inc.
−Removed: 2021 Incentive Award Plan
+Added: 10.1* Compensation Adjustment Letter dated May 30, 2025, between Ginkgo Bioworks, Inc.
+Added: and Steven Coen
+Added: 10.2* Ginkgo Bioworks Holdings, Inc.
+Added: Amended and Restated Non-Employee Director Compensation Program
31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
Ginkgo Bioworks Holdings, Inc.
+Added: August 7, 2025
/s/ Jason Kelly
Chief Executive Officer (Principal Executive Officer)
−Removed: /s/ Mark Dmytruk
−Removed: Chief Financial Officer (Principal Financial Officer)
+Added: August 7, 2025
/s/ Steven Coen
−Removed: Chief Accounting Officer (Principal Accounting Officer)
+Added: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.